Elaine McVey1, Steven Keith2, Joshua K Herr3, Diane Sutter3, Ronald J Pettis4. 1. BD Technologies, Research Triangle Park, NC, USA MaxPoint Interactive, Morrisville, NC, USA. 2. BD Technologies, Research Triangle Park, NC, USA Parker Hannifin Corporation, Madison, WI, USA. 3. BD Technologies, Research Triangle Park, NC, USA. 4. BD Technologies, Research Triangle Park, NC, USA Ron_J_Pettis@bd.com.
Abstract
BACKGROUND: This study sought to assess the function and delivery reliability of intradermal (ID) infusion sets used with commercial insulin pumps. METHOD:Healthy subjects (n = 43) were randomized to either ID or subcutaneous (SC) arms, and received basal/bolus placebo delivery for 24 hours. Subjects received 4 of 8 infusion set combinations (ID: microneedle design A or B, with 2 pump brands [Animas or MiniMed]; SC: Teflon Quickset or steel Rapid-D, Animas pump only, with or without overtaping) and were evaluated for pump occlusion alarms, fluid leakage, pain, and tissue tolerability. A novel algorithm was developed to determine flow consistency based on fluid pressure, and the duration and occurrence rate for periods of unalarmed but interrupted flow ("silent occlusions'") were compared. RESULTS: ID delivery was successfully maintained over the 24-hour infusion period. The number of silent occlusions was lower for ID microneedle cannula design B than A (P < .01) and lower for Rapid-D SC device compared to Quick-set (P = .03). There was no significant difference in the number of occlusion alarms between the ID and SC devices with the Animas pump. However, the pumps tested with ID devices had significantly different alarm rates (MiniMed 29.5%, Animas 0%, P < .001). Leakage and tissue tolerability were comparable across devices. CONCLUSION: The ID infusion set reliably delivered diluent for an extended 24-hour period in healthy subjects and was well tolerated. Silent occlusion flow interruptions could be detected in both ID and SC infusion sets using a proprietary algorithm. This algorithm is a promising method for quantitatively evaluating infusion set flow performance.
RCT Entities:
BACKGROUND: This study sought to assess the function and delivery reliability of intradermal (ID) infusion sets used with commercial insulin pumps. METHOD: Healthy subjects (n = 43) were randomized to either ID or subcutaneous (SC) arms, and received basal/bolus placebo delivery for 24 hours. Subjects received 4 of 8 infusion set combinations (ID: microneedle design A or B, with 2 pump brands [Animas or MiniMed]; SC: Teflon Quickset or steel Rapid-D, Animas pump only, with or without overtaping) and were evaluated for pump occlusion alarms, fluid leakage, pain, and tissue tolerability. A novel algorithm was developed to determine flow consistency based on fluid pressure, and the duration and occurrence rate for periods of unalarmed but interrupted flow ("silent occlusions'") were compared. RESULTS: ID delivery was successfully maintained over the 24-hour infusion period. The number of silent occlusions was lower for ID microneedle cannula design B than A (P < .01) and lower for Rapid-D SC device compared to Quick-set (P = .03). There was no significant difference in the number of occlusion alarms between the ID and SC devices with the Animas pump. However, the pumps tested with ID devices had significantly different alarm rates (MiniMed 29.5%, Animas 0%, P < .001). Leakage and tissue tolerability were comparable across devices. CONCLUSION: The ID infusion set reliably delivered diluent for an extended 24-hour period in healthy subjects and was well tolerated. Silent occlusion flow interruptions could be detected in both ID and SC infusion sets using a proprietary algorithm. This algorithm is a promising method for quantitatively evaluating infusion set flow performance.
Authors: Richard L Weinstein; Sherwyn L Schwartz; Ronald L Brazg; Jolyon R Bugler; Thomas A Peyser; Geoffrey V McGarraugh Journal: Diabetes Care Date: 2007-03-02 Impact factor: 19.112
Authors: R Paul Wadwa; Rosanna Fiallo-Scharer; Brandon Vanderwel; Laurel H Messer; Erin Cobry; H Peter Chase Journal: Diabetes Technol Ther Date: 2009-06 Impact factor: 6.118
Authors: Arianne C van Bon; Bruce W Bode; Caroline Sert-Langeron; J Hans DeVries; Guillaume Charpentier Journal: Diabetes Technol Ther Date: 2011-04-02 Impact factor: 6.118
Authors: Christopher Rini; Bruce C Roberts; Didier Morel; Rick Klug; Benjamin Selvage; Ronald J Pettis Journal: J Diabetes Sci Technol Date: 2019-03-17
Authors: Kevin Verhoeff; Sarah J Henschke; Braulio A Marfil-Garza; Nidheesh Dadheech; Andrew Mark James Shapiro Journal: Cells Date: 2021-01-30 Impact factor: 6.600